XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 2 Months Ended 9 Months Ended
Nov. 09, 2023
Oct. 03, 2023
Sep. 29, 2023
Nov. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Subsequent Event [Line Items]            
Common stock, shares authorized         490,000,000 490,000,000
Shares exercised during the period         8,000  
Preferred stock, par value         $ 0.0001 $ 0.0001
Preferred Tranche A Warrants [Member]            
Subsequent Event [Line Items]            
Warrants exercisable, description   The Preferred Tranche A Warrants are exercisable commencing on the Issuance Date (as defined in the Form of Preferred Tranche A Warrant) until the earlier of (i) fifteen (15) trading days following the date of public announcement of the fulsome data set from the Sanofi S.A. Protect trial and (ii) December 15, 2023. If any purchaser in the September 2023 Offering fails to exercise their Preferred Tranche A Warrant in full prior to its expiration date, such purchaser will forfeit all Preferred Tranche A Warrants, Preferred Tranche B Warrants and Preferred Tranche C Warrants issued to such purchaser.        
Series A-1 Preferred Stock [Member]            
Subsequent Event [Line Items]            
Preferred stock, par value     $ 0.63      
Securities Purchase Agreement [Member] | Series A-1 Preferred Stock [Member]            
Subsequent Event [Line Items]            
Preferred stock, par value     $ 0.0001      
Gross proceeds from private placement     $ 7,500      
Securities Purchase Agreement [Member] | Series A-2 Preferred Stock [Member]            
Subsequent Event [Line Items]            
Preferred stock, par value     $ 0.0001      
Securities Purchase Agreement [Member] | Private Placement [Member] | Forecast [Member]            
Subsequent Event [Line Items]            
Aggregate offering price       $ 67,100    
Securities Purchase Agreement [Member] | Private Placement [Member] | Preferred Tranche A Warrants [Member]            
Subsequent Event [Line Items]            
Preferred stock, par value     $ 0.0001      
Aggregate exercise price     $ 70,500      
Securities Purchase Agreement [Member] | Private Placement [Member] | Preferred Tranche A Warrants [Member] | Forecast [Member]            
Subsequent Event [Line Items]            
Number of shares issued       59,654    
Shares exercised during the period       59,654    
Aggregate exercise price       $ 59,700    
Securities Purchase Agreement [Member] | Private Placement [Member] | Preferred Tranche B Warrants [Member]            
Subsequent Event [Line Items]            
Preferred stock, par value     $ 0.0001      
Aggregate exercise price     $ 52,000      
Securities Purchase Agreement [Member] | Private Placement [Member] | Preferred Tranche C Warrants [Member]            
Subsequent Event [Line Items]            
Preferred stock, par value     $ 0.0001      
Aggregate exercise price     $ 130,000      
Securities Purchase Agreement [Member] | Private Placement [Member] | Series A-1 Preferred Stock [Member]            
Subsequent Event [Line Items]            
Number of shares issued     7,500      
Preferred stock, par value     $ 0.0001      
Aggregate offering price     $ 7,500      
Subsequent Event [Member]            
Subsequent Event [Line Items]            
Common stock, shares authorized   800,000,000        
Subsequent Event [Member] | Preferred Tranche B Warrants [Member]            
Subsequent Event [Line Items]            
Warrants exercisable, description   The Preferred Tranche B Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche B Warrant) until the later of (i) 15 days following the Company’s announcement of data from its SAB-142-101 clinical trial and (ii) March 31, 2025.        
Subsequent Event [Member] | Preferred Tranche C Warrants [Member]            
Subsequent Event [Line Items]            
Warrants exercisable, description   The Preferred Tranche C Warrants are exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche C Warrant) until the five (5) year anniversary of the Exercisability Date.        
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Private Placement [Member] | Preferred Tranche A Warrants [Member]            
Subsequent Event [Line Items]            
Shares exercised during the period 16,269          
Unexercised warrants 27,115          
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Private Placement [Member] | Preferred Tranche B Warrants [Member]            
Subsequent Event [Line Items]            
Shares exercised during the period 10,846          
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Private Placement [Member] | Preferred Tranche C Warrants [Member]            
Subsequent Event [Line Items]            
Shares exercised during the period 27,115          
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Private Placement [Member] | Series A-1 Preferred Stock [Member]            
Subsequent Event [Line Items]            
Number of shares issued 59,654 7,500        
Aggregate exercise price $ 59,650          
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Private Placement [Member] | Series A-3 Preferred Stock [Member] | Preferred Tranche B Warrants [Member]            
Subsequent Event [Line Items]            
Outstanding warrants 42,846          
Aggregate exercise price $ 42,850          
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Private Placement [Member] | Series A-3 Preferred Stock [Member] | Preferred Tranche C Warrants [Member]            
Subsequent Event [Line Items]            
Outstanding warrants 107,115          
Aggregate exercise price $ 107,100